Our study demonstrates that in ovarian cancer, TNFR2 expression can be selectively decreased on all T cells, and predominantly on Tregs, by blockade of bioactive IL-6 within ascites. The gene discussed is TNFRSF1B; the disease is ovarian carcinoma.